Is Myo-inositol better than Metformin for treatment of PCOS Overweight Patients ?
Abstract
Objective: In PCOS patients, the mean BMI was compared between Myo-inositol and Metformin.
Methodology: This Randomized Control Trial was conducted at Department of Gynaecology and Obstetrics, P.A.E.C General Hospital, Islamabad, from May 24, 2017 to Nov 24, 2017. To choose a volunteer for the study, non-probability sequential sampling was utilized. All women diagnosed with PCOS having age between 15 and 40 were included in our study. There were two groups of participants: one group got myoinositol 1 gm twice a day, and the other group received 250 mg metformin pill thrice a day for the duration of the experiment. After three months of medication treatment, the patients were contacted for a follow-up, and all of their baseline measures were retaken. Comparisons between baseline and post-treatment BMI were made. Student & independent sample t-test was applied. P-value 0.05 was deemed significant.
Results: The research comprised a total of 152 patients. Patients were an average of 27.4 years old, with a standard deviation of 7.6. Significantly better efficacy of my-inositol in terms of BMI (t= -9.89, P=0.000, C.I=95% ) than Metformin in polycystic ovary syndrome patients was found.
Conclusion: Myo-inositol was more effective than Metformin at reducing BMI consistently in polycystic ovary syndrome.
Copyright (c) 2022 Journal of The Society of Obstetricians and Gynaecologists of Pakistan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.